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Discussion
Dr Richard D. Weisel (Toronto, Ontario, Canada). If you think
that the major difference is related to the fact that the cells were
cultured, it is possible that they contained some of the cytokines
that were used in the culturing process? I presume that you used
fetal bovine serum as one of the cytokines. If the cytokines are the
important component here, perhaps you need to seed either the
cells or the acellular tissue with cytokines in addition to the cells.
What are your thoughts?
Dr Vincentelli. We did not investigate this issue about the
cytokines precisely, but this remains a possibility. We focused
more on the possibility that the selection of cultured MSCs could
limit the inflammatory process owint to the scaffold xenoantigens,
partly because hematopoietic stem cells were excluded from our
population of bone marrow stem cells. But we have not investi-
gated the effects of medium cytokines yet.
Dr Francisco Diniz Affonso da Costa (Curitiba, Brazil). We
also have done a lot of experiments in sheep with decellularized
allografts from sheep to sheep. What we found is that there is
partial re-endothelialization and partial repopulation just with the
decellularized allografts. We agree with you that you need to seed
some cells, either endothelial cells and fibroblasts or maybe stem
cells, as you showed. What do you think is the best method to seed
these mesenchymal cells in the valves? Do you just put it there and
leave it there or do you have to inject inside the wall or inside the
cusps or both? What do you think is the best method to do that?
Dr Vincentelli. Thank you for your comment and your inter-
esting question. We have used the injection in the matrix with a
very thin needle, just as used for injection of myoblasts in the
myocardium. We found that the same technique could be used for
the injection of the cells in the valve matrix. Cells were injected
only in the arterial wall, and not in the cusps, which are too thin.
Other team used seeding in vitro in a bioreactor. We have hypoth-
esized that we could skip this step and use the animal as a
bioreactor. However, we have no direct evidence that the injected
cells will directly grow in the matrix. We hypothesize that injected
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cells might enhance the autologous recellularization and that in-
jection just before implantation is just a booster for autologous
recellularization.
Dr Weisel. The difficulty is that you need to demonstrate that
you have an increased survival of the implanted cells by your
technique, because you would anticipate that if you had it in a
bioreactor for 7 days beforehand, you would have a full difference
in the number of cells that were available in the decellularized
matrix before implantation. Of course, if you think the biologic
activity is related to the function of those cells, they need to be
alive, they need to function, they need to produce the cytokines
that are most effective, and that would probably only happen if
they had been seeded as opposed to injected immediately before
the present implantation. It is a question that will need to be
addressed in further studies.
Are there any other questions and do you have any response?
Dr Vincentelli. I agree with your comment. We think that we
have still a long way to go. One of the next key points will be the
long-term labeling of new cells to evaluate their outcome. This
should help to determine whether injected cells engraft, proliferate,
and eventually differentiate in situ or send chemotactic and growth
signals to other host cells.
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